Event Abstract Back to Event The yin and yang of the terminal non-lytic complement pathway Kheir Eddine KERBOUA1*, Zineb Hadjidj2, Warda MEZIANE2, Amina BOUMEDIENE1 and Mourad Aribi2 1 Unite of Immunology, Military University Hospital of Oran, Algeria 2 Laboratory of Applied Molecular Biology andn Immunology, University of Tlemcen, Algeria The anaphylatoxins C5a and C3a are bioactive products generated for the terminal non-lytic complement pathway, known for their ability to recruit inflammatory cells, induce oxidative stress, trigger signaling of survival and anti apoptotic responses, control innate and adaptive immunity, and take part in the body’s growth and maintenance. Firstly, we highlight their benefic role in the brain by activating MAPK and AKT signaling in leukocytes and protect neurons against cell death and their help for spur microglia to eliminate the damaged connections; then we see their implication in skeleton, illustrated by the 3MC syndrome; and finally in spurs damaged organs like liver injured which repair itself by C3a and C5a in via the upregulatation of the hepatocyte growth factor-c-Met axis. Secondly, we highlight the dark side of these anaphylatoxins via their implication in various illnesses, including immune related conditions such as sepsis, rheumatoid arthritis, and organ transplant rejection; and non immune related conditions such as osteoarthritis and age-related macular degeneration. Compelling evidence based on the cancer immunoediting theory has been reported emerging data on the relationship between complement and cancer progression where tumor cells under the immunological pressure develop a variety of strategies to avoid complement-mediated damage and the expansion of new tumor populations that are able to control complement activation. Here we will review the contribution of The C5a/C5aR axis to lung cancer progression, emphasizing the upregulatation of phospholipase C2, phospholipase D, cyclins E and D1 and the transactivation of epidermal growth factor receptor. At the end, we illustrate the importance of these biomolecules by the armory of therapeutic inhibitors that has been proposed like eculizumab, cinryze, compstatin, TT30, and the C5a/C5aR axis inhibitor PMX-53 Keywords: C5a, C3a, benefic role, dark side, therapeutic inhibitors Conference: The First International Congress of Immunology and Molecular Immunopathology (CIMIP2014), Tlemcen, Algeria, 17 Oct - 20 Oct, 2014. Presentation Type: Poster Presentation Topic: Immunodeficiencies Citation: KERBOUA K, Hadjidj Z, MEZIANE W, BOUMEDIENE A and Aribi M (2014). The yin and yang of the terminal non-lytic complement pathway. Front. Immunol. Conference Abstract: The First International Congress of Immunology and Molecular Immunopathology (CIMIP2014). doi: 10.3389/conf.fimmu.2014.04.00032 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 01 Dec 2014; Published Online: 01 Dec 2014. * Correspondence: Mr. Kheir Eddine KERBOUA, Unite of Immunology, Military University Hospital of Oran, Orna, Algeria, K.K.Eddine@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Kheir Eddine KERBOUA Zineb Hadjidj Warda MEZIANE Amina BOUMEDIENE Mourad Aribi Google Kheir Eddine KERBOUA Zineb Hadjidj Warda MEZIANE Amina BOUMEDIENE Mourad Aribi Google Scholar Kheir Eddine KERBOUA Zineb Hadjidj Warda MEZIANE Amina BOUMEDIENE Mourad Aribi PubMed Kheir Eddine KERBOUA Zineb Hadjidj Warda MEZIANE Amina BOUMEDIENE Mourad Aribi Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Read full abstract